Hospital-based opioid treatment: Expanding and sustaining the model in Texas

Christopher Moriates, Alanna Boulton, Blair Walker, Rachel Holliman, Nicholaus Christian, John Weems, Emily Humphry, Sara Young, Richard Bottner, Jennifer Potter

Producción científica: Articlerevisión exhaustiva


This Brief Report includes follow-up data about the sustainability and expansion of the Buprenorphine Team (B-Team), a hospital-based opioid treatment (HBOT) program. Between September 2018 and January 2023, the B-Team started 398 patients with opioid-use disorder (OUD) on buprenorphine therapy and coordinated outpatient care for 353 patients before discharge. Two-hundred and forty-nine of these patients were scheduled for follow-up at our partner addiction treatment clinic. Retention rates at our partner clinic remain relatively high: 73 patients (36% of eligible patients) continued to attend appointments between 6 and 12 months, and 40 of 180 patients (22%) who have been discharged from the hospital for at least 1 year continued to attend appointments. This model has been adopted at three additional Texas hospitals, resulting in rapid growth: 1037 patients were started on buprenorphine across these four sites during 2021–2022. Our longitudinal results support HBOT as an effective model for treating patients with OUD.

Idioma originalEnglish (US)
Páginas (desde-hasta)1109-1112
Número de páginas4
PublicaciónJournal of hospital medicine
EstadoPublished - dic 2023

ASJC Scopus subject areas

  • Fundamentals and skills
  • Care Planning
  • Assessment and Diagnosis
  • Health Policy
  • Leadership and Management
  • Internal Medicine


Profundice en los temas de investigación de 'Hospital-based opioid treatment: Expanding and sustaining the model in Texas'. En conjunto forman una huella única.

Citar esto